U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110441) titled 'Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers' on July 25.
Brief Summary: A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Acute-on-Chronic Liver Failure
Intervention:
DRUG: Single Dose G1090N
Subjects will receive single ascending doses of G1090N up to 1200mg.
DRUG: Multiple dosing of G1090N
Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Genfit
Disclaimer: Cu...